TP53 and colorectal carcinoma: A recent study showed that METTL14 can be transcriptionally activated by wild-type p53 and can inhibit the expression of SLC2A3 and PGAM1, thus suppressing aerobic glycolysis, CRC malignant phenotype of p53-WT CRC (133).